Biological Product Manufacturing Market

Biological Product Manufacturing Market: Global Industry Analysis and Forecast 2017 - 2025

Market Overview

The biological product manufacturing is a complex process which produces products derived from recombinant DNA technology to develop a series of processes to manufacture therapeutic products. A biological product can be a virus, antitoxin, vaccine, blood component or derivative, allergenic product, or analogous product, or any therapeutic serum used for the treatment of a disease in humans. These biological products were developed from multicellular systems comprising of plants, animals, unicellular organisms and a mammalian cell. Biological products are composed of sugars, nucleic acids or combination of both.

 During the 20th century, the world witnessed many great discoveries in the biological product manufacturing industry. One of the first biological products to be introduced in the U.S. market was a blood protein known as Factor VIII which was first sold in 1966.The first FDA approved modern biological product designed for human therapeutic use was insulin; the approval was given in 1982.

During 1985, FDA approved human growth hormone (HGF).The manufacturing of biological product differs from product to product; the process involves product-specific process consideration. One very important step involved in biological product manufacturing is controlled the environmental control of particulate and microbial contamination of the biological product production facility. The difference between biological products and conventional drug are, the biological product is heat sensitive and are prone to cross-contamination. Therefore they require a contaminant free environment during manufacturing

Biological product manufacturing facilities use analytical and process development capabilities for the developing and scaling up the process for increased production maintaining the quality of the biological product. The implementation of such process control assist the Phase 1 clinical studies which focus on the product safety and efficacy.

The biological product manufacturing is governed by many various regulatory authorities which make it harder for products approvals, because of overlapping opinions and other redundancies. Therefore to bring all regulatory authorities under one roof, the international conference on harmonization of technical requirements was formed in 1990 for the registration of pharmaceuticals for human use. The ICH has helped biological product manufacturers to register and develop a better quality product which is safe and more efficient.

The biological products are produced in three ways: by developing ways to achieve commercial production of the substance to be used, by gene alteration of the molecule and finally by developing an entirely new substance. Some of the tools used by modern day researcher in the manufacturing of biological products are recombinant DNA and monoclonal antibodies.

Recombinant DNA involves altering of the DNA chain of one organism with desired DNA molecule to produce a novel biological product. Monoclonal antibodies were developed from single cell cultures using cloning techniques; these were designed to fight against toxins, viruses, and cancer cells. The first genetically engineered biological product approved for use in the U.S. was a vaccine for hepatitis-B which was approved in 1986, in the same year, other biological products like therapeutic monoclonal antibodies (MAB’s) and alpha interferon’s were approved.

The biological product manufacturing strictly follows GMP (Good manufacturing practices) rules for all production process from beginning to the last step for biological product manufacturing. These guidelines imply to the change in facility, manufacturing processes and other guidelines regarding clinical trials of the biological product related to its safety and purity. The major drivers for biological product manufacturing market increase in population, increasing the incidence of chronic diseases and increased government initiatives.

 However, the major restraining factors for biological product manufacturing market are the high cost of manufacturing of biological products, high level of price competition amongst competitors and efficacy and reliability of the biological product.

The biological product manufacturing market is segmented by product type, end-user, and region:

Product Type

  • Monoclonal Antibodies
  • Recombinant Proteins
  • Growth Hormones
  • Beta Interferon
  • Therapeutic Enzymes
End-User
  • Hospitals
  • Specialized clinics
  • Government research institutes 

By regional presence, global biological product manufacturing market is segmented into five key regions viz.  North America, Latin America, Europe, Asia-Pacific-Pacific, and the Middle East & Africa. The region of North America is a forerunner in biological product manufacturing market globally mainly because of strong product development, technological advancements and increasing the population. The North America market is closely followed by Europe and Asia-Pacific. The region of Asia Pacific is an emerging market for referral management system mainly because of increasing proficiency in IT skills and growing healthcare expenditure in the region.

The leading players in the referral management market are Novartis AG, F.Hoffmann-La Roche Ltd., Merck & Co., Inc., Bayer AG, Lonza, China Biologic Products, Inc., Pfizer Inc., Sanofi, GOLDEN WEST BIOLOGICALS, Inc., Teva Pharmaceutical Industries Ltd., Amgen Inc.

Find Out More about the Report Coverage

Recommendations

Global Market Study on Next Generation Centrifuge: Asia Pacific and Europe Regional Markets to Lead in Terms of CAGR During 2017-2025

Global Next Generation Centrifuge Market - check share, size, revenue, CAGR, regional outlook, key players, competitive landscape, top manufacturers & forecast.

Global Market Study on Fluoroscopy and C - Arms: C - Arms Segment Estimated to Account for 74.4% Revenue Share by 2016 End

Global Fluoroscopy & C – Arms market is likely to exhibit a CAGR of 4.5% during 2016–2024 with market revenue expected to increase from US$ 2,901.3 Mn in 2015 to US$ 4,290.5 Mn by 2024.

Global Market Study on Peripherally Inserted Central Catheters: Power Injected Peripherally Inserted Central Catheters Product Type Segment to Dominate the Market Through 2024

Global peripherally inserted central catheters market is projected to register a CAGR of 5.8% during the forecast period 2016 – 2024 in terms of value & revenue.

Global Market Study on Diabetic Gastroparesis Treatment : Drugs Product Type Segment Expected to Account for Maximum Revenue Share by 2024

Global diabetic gastroparesis treatment market is expected to register a CAGR of 4.1% over the forecast period and reach a market valuation of US$ 3,769.3 Mn by 2024.

Talk Show:

The Rise of Intelligent Packaging

Personalized, Connected and Sustainable

November 18, 2021 11:00-11:45 AM PST (USA & Canada)
This is a LIVE session
Future Market Insights MarketNgage

Our Clients

Our Clients